University Hospitals of North Midlands NHS Trust

Royal Stoke University Hospital
Data, Security and Protection
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Email foi@uhnm.nhs.uk

Ref: FOIA Reference 2023/24-086

Date: 1st June 2023

Dear

I am writing to acknowledge receipt of your email dated 12th May 2023 requesting information under the Freedom of Information Act (2000) regarding Chronic Lymphocytic Leukaemia

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 How many patients has your Organisations treated in the past 3 months for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Organisation do you refer patients needing treatment to?

A1 I can neither confirm nor deny whether the information you have requested is held by the Trust in its entirety. This is because the information requested in this question is not held centrally, but may be recorded in health records (We would have to go through every diagnosed CLL patient and cross reference with their pathway on Medway and/or clinical letter and manually count). In order to confirm whether this information is held we would therefore have to individually access all health records within the Trust and extract the information where it is present. We therefore estimate that complying with your request is exempt under section 12 of the FOI Act: cost of compliance is excessive. The section 12 exemption applies when it is estimated a request will take in excess of 18 hours to complete. We estimate that accessing and reviewing all health records and then extracting relevant information would take longer than the 18 hours allowed for. In addition to the section 12 exemption the Trust is also applying section 14 (1) exemption: *oppressive burden on the authority*

Q2 How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following?

BR (bendamustine + rituximab)
Calquence (acalabrutinib)
FCR (fludarabine + cyclophosphamide + rituximab)
Gazyva (obinutuzumab) + chlorambucil
Imbruvica (ibrutinib)
Venclexta (venetoclax)
Venclexta (venetoclax) + Gazyva (obinutuzumab)
Venclexta (venetoclax) + rituximab

Zydelig (idelalisib) + rituximab
Any other systemic anti-cancer therapy
Wait and watch (monitoring only, no active treatment)

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information.* However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:

BR (bendamustine + rituximab) - 0
Calquence (acalabrutinib) - 44
FCR (fludarabine + cyclophosphamide + rituximab) - 0
Gazyva (obinutuzumab) + chlorambucil - 0
Imbruvica (ibrutinib) - 10
Venclexta (venetoclax) – 0
Venclexta (venetoclax) + Gazyva (obinutuzumab) - 6
Venclexta (venetoclax) + rituximab - <5
Zydelig (idelalisib) + rituximab - 0
Any other systemic anti-cancer therapy - 0
Wait and watch (monitoring only, no active treatment)

Q3 If your Organisation does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any on-going clinical trials for the treatment of CLL? If so, can you please provide the name of each trial along with the number of patients taking part?

A3 See below:

Project Short title	Recruited (org)
Investigating DNA damage repair defects in Haematological malignancies	0
FLAIR	25
EPIC - NIS in CLL patients treated with acalabrutinib through the EAP	11
IMPROVE study: The IMpact of Pausing BTKi therapy in Blood Cancer	24

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,

Rachel Montinaro
Data Security and Protection Manager - Records